Abstract
Clenbuterol hydrochloride (CLT), β2 adrenergic agonist is
used as a bronchodilator in the therapeutic treatment of asthma. It is
important to know the stability behaviour of the drug in different
degradation conditions as per ICH Q1A (R2) guidelines for safety and
efficacy purpose. The main objective of the study is to develop and validate
stability indicating LC-MS/MS method for the determination of
Clenbuterol HCl. The separation was achieved using Phenomenex Gemini NX C18
(250*4.6 mm, 5 μ) column and the mobile
phase consisting of ammonium acetate buffer (5 mM), 0.15%
triethylamine (TEA), pH 7.5 with acetic acid: methanol (70:30, v/v)
at flow rate 1 ml/min. The detection was done using PDA
detector at 245 nm. The validation was performed as per ICH Q2 (R1)
guideline. The drug was subjected to stress degradation conditions as per
ICH Q1A (R2) guidelines. The significant degradation was observed in acidic
(8.78%) and sunlight (liquid) (9%) condition while no
degradation was observed in neutral, basic, oxidation and thermal condition.
The drug and its degradation products were characterized using
LC-MS/MS and the proposed degradation mechanism was communicated.
The developed method was found to be stability-indicating, simple, specific,
selective, sensitive, linear, accurate, robust and precise and used as a
routine analysis in quality control laboratory.
Key words
anti-asthma/COPD drugs - chemistry - drug research